Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor
Placenta · 2025
DOI: 10.1016/j.placenta.2024.12.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Placenta, 2025. Verfasst von Jennifer H Yo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Monash Health, Clayton, VIC, Australia; The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sc…. Hauptthemen laut MEDLINE: Tacrolimus, Human Umbilical Vein Endothelial Cells, Immunosuppressive Agents, Placenta Growth Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Tacrolimus is a cornerstone of immunosuppression in solid organ transplants, but its use is linked with the development of endothelial dysfunction. Pregnant solid organ transplant recipients are four to six times more likely to develop preeclampsia, which is also associated with endothelial dysfunction. Therefore, this in vitro study investigated the acute effects of tacrolimus on the expression of common angiogenic factors related to preeclampsia, and effects on angiogeneis in primary human tissues. METHODS: Primary human umbilical vein endothelial cells (HUVECs) were exposed to tacrolimus (0, 5, 20, 50 ng/mL) for 24h alone, or in combination with tumour necrosis factor (TNF, 10 ng/mL) and high dose glucose (25 mM). Cell culture concentrations of sFlt-1, PlGF and activin A were measured. In addition, the effect of tacrolimus on markers of endothelial dysfunction and permeability were assessed, as were the effect of tacrolimus on tube formation. Angiogenic factors and mRNA markers of oxidative stress and inflammation were also assessed in primary placental tissue after an acute 24 h exposure to tacrolimus. RESULTS: Tacrolimus exposure significantly reduced HUVEC secretion of PlGF, increased production of activin A, andreduced tubular structure formation without impacting cell permeability or viability. There was no change in ICAM1 or VCAM1 expression in HUVECs treated with tacrolimus treatment alone, however co-culture with TNF significantly increased expression of ICAM1 and VCAM1. In placental explants tacrolimus did not change angiogenic factor production or markers of inflammation or oxidative stress. CONCLUSION: An acute tacrolimus exposure reduced PlGF secretion and impaired angiogenesis in primary endothelial cells, without affecting. These findings provide a potential mechanistic basis for tacrolimus to contribute to the endothelial dysfunction contributing to preeclampsia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Monash Health, Clayton, VIC, Australia; The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Department of Medi…
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Clayton, VIC, Australia; Monash Women's, Monash Health, Clayton, VIC, Australia.
- Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia.
- Department of Nephrology, Monash Health, Clayton, VIC, Australia.
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
Zitieren
APA
Yo, J. H., Palmer, K. R., Nikolic-Paterson, D., Kerr, P. G., & Marshall, S. A. (2025). Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor. Placenta. https://doi.org/10.1016/j.placenta.2024.12.010
Vancouver
Yo JH, Palmer KR, Nikolic-Paterson D, Kerr PG, Marshall SA. Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor. Placenta. 2025. doi:10.1016/j.placenta.2024.12.010
BibTeX
@article{Yo2025,
author = {Yo, Jennifer H and Palmer, Kirsten R and Nikolic-Paterson, David and Kerr, Peter G and Marshall, Sarah A},
title = {Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor},
journal = {Placenta},
year = {2025},
doi = {10.1016/j.placenta.2024.12.010}
}
EUVIMED